|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
12/27/2012 8:16:32 AM
Accentia Biopharmaceuticals Inc. and its majority-owned subsidiary, Biovest International Inc., trimmed some of the red ink from their operating statements in fiscal 2012. Accentia (OTCQB: ABPI) reported a loss attributable to common shareholders of $4.3 million, or 5 cents a share, for the year ended Sept. 30, compared to a loss attributable to common shareholders of $11.6 million, or 17 cents a share, in the same period one year ago. Revenue for fiscal 2012 was $4.1 million, a 2.5 percent increase from the prior year. The FY 2012 net loss at Biovest (OTCQB: BVTI) was $11.8 million, or 8 cents a share, compared to a net loss of $15.3 million, or 11 cents a share, in the prior year.
|
|
|
|
|
|
|
|
|
|
|